Multiple T-cell and lymphocyte surface antigens

Multiple T-cell and lymphocyte surface antigens refers to a collective group of proteins expressed on the surface of T-lymphocytes and other immune cells that serve as the therapeutic target for polyclonal antibody preparations. These antigens include a diverse array of Cluster of Differentiation (CD) markers such as CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, and CD45, as well as HLA class I and II molecules (FDA Label, Thymoglobulin). The interaction between therapeutic antibodies and these various antigens leads to the rapid and profound depletion of circulating T-cells via mechanisms like complement-mediated lysis and apoptosis (PubMed, PMID: 11436205). This broad-spectrum immunosuppressive approach is clinically utilized primarily for the prevention and treatment of acute organ transplant rejection and the management of severe aplastic anemia. By targeting multiple receptors simultaneously, these therapies effectively disrupt various pathways of T-cell activation, adhesion, and proliferation. However, the non-specific nature of targeting multiple antigens also contributes to significant safety concerns, including cytokine release syndrome and an increased susceptibility to infections (StatPearls, Antithymocyte Globulin). This entry is considered 'incorrect' as a canonical target because it represents a grouping of distinct molecular entities rather than a single specific protein.

Other names

T-lymphocyte antigensLymphocyte surface antigensThymocyte antigensT-cell surface markers

Depletion of T-lymphocytes from the circulation through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and the induction of apoptosis, alongside the modulation of surface receptors involved in T-cell activation and leukocyte adhesion (DrugBank DB00033; StatPearls, Antithymocyte Globulin).